Eckert & Ziegler AG recently signed an agreement with Point Biopharma Global for the supply of carrier-free lutetium-177 (Lu-177).
The agreement has a term of 10 years with a total sales volume of more than 100 million euros. Eckert & Ziegler said the Lu-177 supply is conditional to successful validation of the company's own Lu-177 with the intended compounds.
Point's supply pipeline meanwhile has multiple Lu-177-based clinical candidates, including one candidate for the treatment of metastatic castration-resistant prostate cancer. The companies said that the agreement's projected sales volume is based on the successful regulatory approval of a Lu-177-based clinical candidate in the future.
Eckert & Ziegler said it plans to invest about 10 million euros in its own site in Wilmington, Massachusetts, U.S., to increase its manufacturing capacities.
This latest supply agreement follows a previously signed actinium-225 supply agreement between the companies in April 2023.